What is it about?
A vaccine to prevent the most widely distributed human malaria caused by Plasmodium vivax is needed. There is no licensed vaccine and current developments have shown limited efficacy. We have developed Rv21, a virus-like particle able to induce high levels of protection against pre-erythrocytic malaria through the induction of antibodies.
Featured Image
Why is it important?
There is no licensed vaccine against any parasitic infection, including malaria. Most vaccine candidates have focused on P. falciparum malaria and very few developments have been produced against P. vivax, which is highly prevalent in South East Asia and Latin America. We have developed a new vaccine candidate that protects against P. vivax malaria, providing information of the capacity to protect against a stringent challenge with transgenic sporozoites expressing the VK210 or VK247 Circumsporozoite protein, a leading vaccine candidate
Perspectives
Demonstrating high efficacy levels to protect against a malaria sporozoite challenge has been key to obtain support for GMP development and clinical trials. Thanks to efficacy demonstration, Rv21 has entered clinical phase and is currently under GMP development
Prof Arturo Reyes-Sandoval
University of Oxford
Read the Original
This page is a summary of: Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models, Scientific Reports, April 2017, Nature,
DOI: 10.1038/srep46482.
You can read the full text:
Contributors
The following have contributed to this page
